Background: Tamoxifen is essential in the treatment of estrogen receptor positive breast cancer. Concentrations of its active metabolite endoxifen > 5.97 ng/mL have been associated with a 26% lower recurrence rate in the adjuvant setting (Madlensky 2011), providing a rationale for therapeutic drug monitoring. However, the risk of high endoxifen concentrations has not been established. Therefore, we investigated whether extremely high endoxifen levels are correlated with a higher incidence of clinically significant toxicities. Methods: Patients receiving adjuvant tamoxifen treatment (20 mg) with a steady state endoxifen level above 25 ng/mL were retrospectively identified in databases of the CYPTAM study (n ¼ 667, NTR 1509) and of samples collected in routine care (n ¼ 1768). The percentage of patients with clinically significant toxicities, defined as toxicities leading to either dose reduction or treatment discontinuation, was compared to the overall tamoxifen population. As historical comparison, studies described in the EBCTCG overview (2011) in which patients received adjuvant tamoxifen (20 mg) and which reported clinically significant toxicities were selected. Results: 26 patients (1.5%) had an endoxifen level > 25 ng/mL, of which 4 patients (15%) had clinically significant toxicities, compared to 10.2% in the overall tamoxifen population (2014)). Reported toxicities were mood disturbances (n ¼ 3), hot flushes (n ¼ 2) and musculoskeletal disorders (n ¼ 1). Median time on treatment was 28 months in patients with high endoxifen levels, compared to 47 months reported in literature. Conclusions: The incidence of clinically significant toxicities is relatively low and is similar in patients with extremely high endoxifen levels and the overall tamoxifen population. Therefore, dose reductions are not indicated in patients with high endoxifen concentrations without toxicity. -89 (22,4%). A median follow-up period was 58 months. Only 94 (21,5%) patients received adjuvant polychemotherapy, combinations adjuvant polychemotherapy and radiation therapy -27 (6,1%) or endocrine therapy -37(8,5%). Results: During a median follow-up period local recurrent were detected at 5 (0,8%), distant metastasis -15 (2,6%) patients. Overall disease-free survival in patients with BCS stage I was 96,2%, IIA-90%, 7%,2% (p>0,05). Overall diseasefree survival in patients with SSM stage I was 92,9%, IIA-91,2%, IIB -84,4%, IIIA -91,4% (p>0,05). The postoperative cosmetic result after BCS was assessed in 79,3% patients. Conclusions: In breast reconstructive the most effective method is using breast tissue after BCS. Oncoplastic surgery contributes is the better phychological adaptation of patients. Variety of modifications and options of reconstructive surgery causes problem of choice, which should be solved with patient taking into account the clinical data. The extent of surgical intervention does not affect the performance of the 5-year overall and recurrent survival and depends on the distribution process.
Background: Male breast cancer is a rare disease that have different outcomes in comparison with the same disease in female counterparts. Due to rarity of its occurrence, data available on breast cancer in male population are relatively scarce. The aim of this study was to summarize data available in the SEER (National Cancer Institute Surveillance, Epidemiology, and End Results) program's database about male breast cancer. SEER incorporates data from 18 cancer registries all over the United States. Data about clinical and epidemiological patterns as well as survival were analyzed and are subsequently presented. Methods: Data were obtained using SEER*Stat version 8.3.5 where (SEER 18 Regs Nov 2017 Submission) database was used as the data source. Only males diagnosed between 2000-2015 with malignant breast cancer, known age, and microscopic confirmation were included. Relative survival was calculated using Ederer II method. Further data analysis was made using SPSS version 21. Results: A total of 6790 patients were identified with a median age of 68. White race constituted the majority of cases (81.3%; n ¼ 5519). Incidence rate was 10.2 per million (95% CI 10 -10.5) with increasing trend over time (annual percent change ¼ 1.9%, p < 0.05). The disease showed slight predilection to occur on the left side (52.3%; n ¼ 3550). Most cases were staged as regional (n ¼ 2974) or localized (n ¼ 3152) at time of diagnosis. The disease was the only primary cancer in 4502 patients (66.3%) and the first of 2 or more primaries in 787 cases (11.6%). It occurred as a second or later multiple primary in remaining cases (22.1%). Median observed survival was 117.2 months with a 5-years and 10-years observed survival of 70.6% (CI: 69.1%-71.9%) and 48.8% (CI: 46.9%-50.6%) respectively. 5-years relative survival was 84% (CI: 82.3%-85.6%) while 10-years relative survival was 71.1% (CI: 68.3%-73.7%). Conclusions: Male breast cancer is a rare tumor with an incidence rate of 10.2 per million. This tumor is more likely to occur in old age and white race and occurs more on left side. Disease occurred as a second (or later multiple) primary in 22% of cases. 5-years relative survival is 84% with a median survival of 117.2 months. Legal entity responsible for the study: Mohamed Alaa Gouda. -89 (22,4%) . A median follow-up period was 58 months. Only 94 (21,5%) patients received adjuvant polychemotherapy, combinations adjuvant polychemotherapy and radiation therapy -27 (6,1%) or endocrine therapy -37(8,5%). Results: During a median follow-up period local recurrent were detected at 5 (0,8%), distant metastasis -15 (2,6%) patients. Overall disease-free survival in patients with BCS stage I was 96,2%, IIA-90%, 7%, 2% (p>0, 05) . Overall diseasefree survival in patients with SSM stage I was 92,9%, 2%, 4%, 4% (p>0, 05) . The postoperative cosmetic result after BCS was assessed in 79,3% patients. Conclusions: In breast reconstructive the most effective method is using breast tissue after BCS. Oncoplastic surgery contributes is the better phychological adaptation of patients. Variety of modifications and options of reconstructive surgery causes problem of choice, which should be solved with patient taking into account the clinical data. The extent of surgical intervention does not affect the performance of the 5-year overall and recurrent survival and depends on the distribution process. 
